Rb1512-130810-WS

A synthetic peptide from internal region of human Sialin (SLC17A5) conjugated to an immunogenic carrier protein was used as the antigen.

Membrane glycoprotein HP59, Sodium/sialic acid cotransporter, AST, Solute carrier family 17 member 5, SLC17A5

FUNCTION: Primary solute translocator for anionic substances; particularly it is a free sialic acid transporter in the lysosomes.
Defects in SLC17A5 are the cause of Salla disease (SD); also known as Finnish type sialuria. SD is a sialic acid storage disease (SASD). SASDs are autosomal recessive neurodegenerative disorders characterized by hypotonia, cerebellar ataxia and mental retardation. They are caused by a defect in the metabolism of sialic acid which results in increased urinary excretion of unconjugated sialic acid, specifically N-acetylneuraminic acid. Enlarged lysosomes are seen on electron microscopic studies. Clinical symptoms of SD present usually at age less than 1 year and progression is slow.
Defects in SLC17A5 are the cause of infantile sialic acid storage disorder (ISSD); also known as N-acetylneuraminic acid storage disease (NSD). ISSD is a severe form of sialic acid storage disease. Affected newborns exhibit visceromegaly, coarse features and failure to thrive immediately after birth. These patients have a shortened life span, usually less than 2 years.
Note=Infantile sialic acid storage disorder is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders.
SUBCELLULAR LOCATION: Lysosome membrane; Multi-pass membrane protein
Tissue specificity: Found in fetal lung and small intestine, and at lower level in fetal skin and muscle. In the adult, detected in placenta, kidney and pancreas. Abundant in the endothelial cells of tumors from ovary, colon, breast and lung, but is not detected in endothelial cells from the corresponding normal tissues.

Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

12 months after reconstitution

This item will be shipped to you at ambient temperature in a lyophilised form.

1. Fu C, et al. Clin. Cancer Res. 7:4182-4194(2001)
2. Verheijen F.W, et al. Nat. Genet. 23:462-465(1999)
3. Schroeder B, et al. Traffic 8:1676-1686(2007)

For research use only

100 µl

Unconjugated antibody

NZ white rabbit

Whole serum

Polyclonal

Polyclonal, whole serum

IHC, WB (confirmed by recombinant protein). A dilution of 1: 200 to 1: 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.

Specific for SLC17A5.

Human. Other species not yet tested.

Lyophilised

Reconstitute in 100 µl of sterile water. Centrifuge to remove any insoluble material.

Control peptide is available at $120 per 50 μg. Please enquire sales@osenses.com

- Click to download the Data Sheet

- Click to download the Material Safety Data Sheet